Neurosurgical Oncology – Long-term Prognosis of Patients with IDH1 Mutant Tumors

Dr. Daniel Cahill, MD, PhD, who is presenting at the 2019 American Association of Neurological Surgeons (AANS) Scientific Sessions, discusses the latest techniques that are helping surgeons at Massachusetts General Hospital to make substantial impacts on long-term prognosis of individuals with IDH1 mutant tumors in patients who are often in their 20s or 30s.

As a neurosurgeon-scientist, Dr. Cahill’s clinical practice is focused on the care of brain tumor patients, improving clinical trials of therapy for these patients, and training neurosurgical residents in the diagnosis and treatment of these cancers.  

Liked it? Take a second to support healthprofessionalradio on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.